Triple Combination of Oncolytic Herpes Simplex Virus-1 Vectors Armed with Interleukin-12, Interleukin-18, or Soluble B7-1 Results in Enhanced Antitumor Efficacy

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Cancer Research

• Publication date

  2006-01-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-05-1494PMID 16428511
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models

  2006cited by this paper
• Development of Oncolytic Replication-Competent Herpes Simplex Virus Vectors

  2005cited by this paper
• An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.

  2005cited by this paper
• Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.

  2005cited by this paper
• Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis

  2004cited by this paper
• Angiogenesis Inhibition by an Oncolytic Herpes Virus Expressing Interleukin 12

  2004cited by this paper
• Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines.

  2003cited by this paper
• ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

  2003cited by this paper
• The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer.

  2003cited by this paper
• Synergy of IL-12 and IL-18 for IFN-γ Gene Expression : IL-12-Induced STAT4 Contributes to IFN-γ Promoter Activation by Up-Regulating the Binding Activity of IL-18-Induced Activator Protein 1

  2002cited by this paper
• Herpes Simplex Virus Type 1 Amplicon Vector-Mediated Gene Transfer to Muscle

  2002cited by this paper
• Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model.

  2002cited by this paper
• Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1.

  2002cited by this paper
• Oncolytic Herpesvirus Effectively Treats Murine Squamous Cell Carcinoma and Spreads by Natural Lymphatics to Treat Sites of Lymphatic Metastases

  2002cited by this paper
• Synergy of IL-12 and IL-18 for IFN-γ Gene Expression: IL-12-Induced STAT4 Contributes to IFN-γ Promoter Activation by Up-Regulating the Binding Activity of IL-18-Induced Activator Protein 11

  2002cited by this paper
• In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.

  2001cited by this paper
• IL-18–stimulated GADD45β required in cytokine-induced, but not TCR-induced, IFN-γ production

  2001cited by this paper
• Cytokine Gene Transfer Enhances Herpes Oncolytic Therapy in Murine Squamous Cell Carcinoma

  2001cited by this paper
• Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.

  2001cited by this paper
• An infectious transfer and expression system for genomic DNA loci in human and mouse cells

  2001cited by this paper
• Interleukin 12 Secretion Enhances Antitumor Efficacy of Oncolytic Herpes Simplex Viral Therapy for Colorectal Cancer

  2001cited by this paper
• Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity.

  2001cited by this paper
• IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production.

  2001cited by this paper
• Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing

  2001cited by this paper
• Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome.

  2001cited by this paper
• IFN-γ-Dependent and -Independent Mechanisms in Adverse Effects Caused by Concomitant Administration of IL-18 and IL-12

  2000cited by this paper
• Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.

  2000cited by this paper
• Upregulation of interleukin-12 receptor on peripheral blood mononuclear cells and HLA class I, HLA class II or ICAM-1 on melanoma cells by B7.1 and interleukin-12: a mechanism for immunostimulatory impact of melanoma cells adenovirally transfected with B7.1 and IL12?

  2000cited by this paper
• Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope

  2000cited by this paper
• Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.

  2000cited by this paper
• Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model

  1999cited by this paper
• Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration

  1999cited by this paper
• Systemic Antitumor Immunity in Experimental Brain Tumor Therapy Using a Multimutated, Replication-Competent Herpes Simplex Virus

  1999cited by this paper
• Corticosteroid Administration Does Not Affect Viral Oncolytic Activity, but Inhibits Antitumor Immunity in ReplicationCompetent Herpes Simplex Virus Tumor Therapy

  1999cited by this paper
• Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes

  1999cited by this paper
• Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18)

  1999cited by this paper
• Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

  1999cited by this paper
• An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

  1998cited by this paper
• Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.

  1998cited by this paper
• In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.

  1998cited by this paper
• IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.

  1998cited by this paper
• Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

  1998cited by this paper
• Therapeutic Efficiency and Safety of a Second-Generation Replication-Conditional HSV1 Vector for Brain Tumor Gene Therapy

  1997cited by this paper
• Transcriptional targeting of herpes simplex virus for cell-specific replication

  1997cited by this paper
• IGIF Does Not Drive Th1 Development but Synergizes with IL-12 for Interferon-γ Production and Activates IRAK and NFκB

  1997cited by this paper
• IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB.

  1997cited by this paper
• IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12.

  1997cited by this paper
• Interleukin‐12 and B7.1 co‐stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors

  1996cited by this paper
• B7-1 and interleukin 12 synergistically induce effective antitumor immunity.

  1995cited by this paper
• Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

  1995cited by this paper
• Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector.

  1992cited by this paper
• Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

  1989cited by this paper
• Genetics of natural resistance to herpesvirus infections in mice

  1975cited by this paper

• Soluble B7 and TNF family in colorectal cancer: Serum level, prognostic and treatment value.

  2025cites this paper
• The key role of immunomodulatory cytokines for the development of novel NK cell-based cancer therapies.

  2025cites this paper
• Oncolytic vaccinia virus expressing non-secreted decoy-resistant IL-18 mutein elicits potent antitumor effects with enhanced safety

  2025cites this paper
• Oncolytic Virus Therapies in Malignant Gliomas: Advances and Clinical Trials

  2025cites this paper
• Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer Therapies.

  2024cites this paper
• Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy

  2024cites this paper
• Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?

  2024influential citation
• Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12

  2023cites this paper
• Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor

  2023cites this paper
• Personalizing Oncolytic Virotherapy

  2023cites this paper
• Personalizing Oncolytic Immunovirotherapy Approaches

  2023cites this paper
• Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements

  2022cites this paper
• Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword

  2022cites this paper
• Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors

  2022cites this paper
• Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models

  2022influential citation
• Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment.

  2022cites this paper
• Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations

  2022cites this paper
• Current strategies in engaging oncolytic viruses with antitumor immunity

  2021cites this paper
• Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy

  2021cites this paper
• The Multifaceted Role of Macrophages in Oncolytic Virotherapy

  2021cites this paper
• Virus-inspired Strategies for Cancer Therapy.

  2021cites this paper
• Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma

  2021cites this paper
• Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis

  2021cites this paper
• The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model

  2020cites this paper
• Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy

  2020cites this paper
• Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1

  2020cites this paper
• Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer

  2020cites this paper
• Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy

  2020cites this paper
• Cytokines in oncolytic virotherapy.

  2020cites this paper
• Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors

  2019cites this paper
• Design and application of oncolytic viruses for cancer immunotherapy.

  2019cites this paper
• Armed oncolytic viruses: A kick-start for anti-tumor immunity

  2018cites this paper
• Evaluation of Oncolytic and Immunomodulatory Potential of the HSV-1 Live-Attenuated Vaccine Strain VC2 in an Immunocompetent Murine Melanoma Model

  2018cites this paper
• Third‐generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice

  2018cites this paper
• Soluble immune checkpoints in cancer: production, function and biological significance

  2018cites this paper
• Targeting Melanoma with Cancer-Killing Viruses

  2017cites this paper
• Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells

  2017cites this paper
• THE PRECLINICAL DEVELOPMENT OF ONCOLYTIC VIRAL IMMUNOTHERAPY FOR EPITHELIAL CANCER

  2017cites this paper
• UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Ex parte NIELS JONAS HEILSKOV GRA VERSEN,

  2017cites this paper
• Immunomodulation Within a Single Tumor Site to Induce Systemic Antitumor Immunity: In Situ Vaccination for Cancer

  2016cites this paper
• To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses

  2016cites this paper
• In situ vaccination for the treatment of cancer.

  2016cites this paper
• Oncolytic Immunotherapy for Treatment of Cancer.

  2016cites this paper
• Oncolytic viruses—immunotherapeutics on the rise

  2016cites this paper
• Neurotropic Viral Infections

  2016cites this paper
• Oncotarget Strategies For Herpes Simplex Virus-1.

  2016cites this paper
• Oncolytic virus therapy: A new era of cancer treatment at dawn

  2016cites this paper
• Viral Oncolysis of Glioblastoma

  2016cites this paper
• Therapeutic effects of bone marrow mesenchymal stem cells expressing interleukin-12 in mice bearing malignant ascites tumor.

  2015cites this paper
• Context‐dependent role of IL‐18 in cancer biology and counter‐regulation by IL‐18BP

  2015cites this paper
• Oncolytic virotherapy using herpes simplex virus: how far have we come?

  2015cites this paper
• In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf

  2015cites this paper
• Selectively Replicating Herpes Simplex Viral Vectors

  2014cites this paper
• Going viral with cancer immunotherapy

  2014cites this paper
• Adenoviral vector-mediated gene therapy for gliomas: coming of age

  2014cites this paper
• Oncolytic Virus Therapy for Malignant Glioma

  2013cites this paper
• Evolution of oncolytic viruses: novel strategies for cancer treatment.

  2013cites this paper
• Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.

  2013cites this paper
• Oncolytic vaccines

  2013cites this paper
• Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.

  2012cites this paper
• CD8+ T cell response mediates the therapeutic effects of oncolytic adenovirus in an immunocompetent mouse model

  2012cites this paper
• HERPESVIRUSES AS ONCOLYTIC AGENTS

  2012cites this paper
• Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.

  2012cites this paper
• Oncolytic herpes simplex virus engineering and preparation.

  2012cites this paper
• Recombinant viral vaccines for cancer.

  2012cites this paper
• Active immunotherapy: oncolytic virus therapy using HSV-1.

  2012cites this paper
• The molecular basis of herpesviruses as oncolytic agents.

  2012cites this paper
• Progress of oncolytic viruses in sarcomas

  2012cites this paper
• Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.

  2012cites this paper
• The Role of TNFα in the Periaqueductal Gray During Naloxone-Precipitated Morphine Withdrawal in Rats

  2011cites this paper
• Engineered herpes simplex virus vectors for antitumor therapy and vaccine delivery

  2011influential citation
• Oncolytic Viruses for the Treatment of Neuroendocrine Tumors

  2011cites this paper
• Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?

  2011cites this paper
• Targeting Angiogenesis for Controlling Neuroblastoma

  2011cites this paper
• Combining Oncolytic Viruses with Cancer Immunotherapy

  2011cites this paper
• The Role of Natural Killer Cells in the Context of Oncolytic Herpes Simplex Virotherapy for Glioblastoma

  2011cites this paper
• Virus Adaptation and Treatment Oncolytic viruses : a step into cancer immunotherapy

  2011cites this paper
• Utilisation du virus de la rougeole en virothérapie anti-tumorale

  2011cites this paper
• Oncolytic viruses: a step into cancer immunotherapy

  2011cites this paper
• HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases.

  2010cites this paper
• Engineering Herpes Simplex Virus for Cancer Oncolytic Virotherapy

  2010cites this paper
• HSV Recombinant Vectors for Gene Therapy

  2010cites this paper
• Oncolytic HSV as a vector in cancer immunotherapy.

  2010cites this paper
• Virally mediated immunotherapy for brain tumors.

  2010cites this paper
• Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment

  2010cites this paper
• New perspectives in cancer virotherapy: bringing the immune system into play.

  2010cites this paper
• HSV Recombinant Vectors for Gene Therapy.

  2010cites this paper
• Therapeutic sentinel lymph node imaging.

  2009cites this paper
• Advances in interleukin-12 gene therapy for acquired liver diseases.

  2009cites this paper
• Gene and Virotherapy Against Osteosarcoma

  2009cites this paper
• Pharmacologic and chemical adjuvants in tumor virotherapy.

  2009cites this paper
• "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.

  2009cites this paper
• Herpes simplex virus oncolytic therapy for pediatric malignancies.

  2009cites this paper
• Adenoviral‐mediated interleukin‐18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats

  2009cites this paper
• Mechanisms of intestinal microsphere uptake and quantitative analysis of organ distribution for applications of oral drug delivery

  2008cites this paper
• “Armed” oncolytic herpes simplex viruses for brain tumor therapy

  2008cites this paper
• Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma.

  2008cites this paper
• Oncolytic virotherapy as a personalized cancer vaccine

  2008cites this paper
• Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy.

  2008cites this paper
• MINI REVIEW Oncolytic virotherapy as a personalized cancer vaccine

  2008cites this paper